Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26??

Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) announced today that it will report its fourth quarter and full-year financial results for 2025 on February 26, 2026, at 7:00 a.m. U.S. Eastern Standard Time (EST). Following this announcement, the company’s Chief Executive Officer, Joe Ciaffoni, along with other key members of the leadership team, will host a live webcast at 8:00 a.m. EST to discuss the results and provide insights into the company's strategy and operational updates.

Investors interested in participating in the presentation can access the live webcast and accompanying materials through the “Investors” section of Indivior’s website at www.indivior.com. A direct link to the live event is available here: https://edge.media-server.com/mmc/p/f78ufsat. Additionally, participants can join the presentation via telephone by registering through this link: https://register-conf.media-server.com/register/BI44fe43e28e334eb58b41edf49f6f80ce. The registration process offers users the option to receive a direct call back just before the event or a call-in number with a unique pin code after registration.

For those unable to attend the live session, a replay will be accessible on the company's website following the event.

Indivior is recognized as a leader in long-acting injectable treatments for opioid use disorder (OUD), dedicated to providing evidence-based solutions and enhancing understanding of OUD as a chronic but treatable condition. With over 25 years of experience in addiction medicine, Indivior emphasizes a commitment to compassion and scientific advancement, aiming to support individuals battling OUD and promote long-term recovery. For further inquiries, investors can reach Jason Thompson at 804-402-7123 or via email, while media inquiries can be directed to Cassie France-Kelly.

As Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) approaches its fourth quarter and full-year 2025 financial results announcement on February 26, 2026, investors should position themselves strategically based on several key factors impacting the company’s performance and future outlook.

Indivior, a market leader in treatments for opioid use disorder (OUD), is poised for a significant presentation from CEO Joe Ciaffoni and his leadership team. Key aspects to watch for during the earnings call and webcast will be the company’s revenue trajectory, especially following the growth or contraction of their long-acting injectable treatments. Any shifts in market dynamics due to regulatory changes or competitive pressures should also be scrutinized.

Investors should consider the ongoing societal and legislative focus on addiction recovery, which can enhance demand for Indivior’s products. Positive trends in public health funding and advocacy for OUD treatments could serve as strong tailwinds for revenue growth. Examine any updates on pipeline candidates or clinical trials as these may signal future product approvals that could expand Indivior's therapeutic portfolio and enhance its market position.

It's also critical to assess whether Indivior’s management provides updated forecasts or guidance, particularly any adjustments to projections based on recent performance or external market factors. Listening to the management's tone and confidence during the call can offer insights into their strategic direction and operational stability.

With potential volatility surrounding earnings announcements, maintaining a watchful eye on pre- and post-earnings price movements can inform trading strategies. Prioritize risk management and remain prepared for fluctuations that often accompany financial disclosures. Overall, Indivior's focus on both scientific rigor and compassionate care positions it well; however, investors should remain vigilant about external pressures that could impact future financial health.